NO20020829D0 - Ny anvendelse av docetaxel for behandling av hepatoma - Google Patents

Ny anvendelse av docetaxel for behandling av hepatoma

Info

Publication number
NO20020829D0
NO20020829D0 NO20020829A NO20020829A NO20020829D0 NO 20020829 D0 NO20020829 D0 NO 20020829D0 NO 20020829 A NO20020829 A NO 20020829A NO 20020829 A NO20020829 A NO 20020829A NO 20020829 D0 NO20020829 D0 NO 20020829D0
Authority
NO
Norway
Prior art keywords
docetaxel
treatment
hepatoma
new use
hepatocellular carcinoma
Prior art date
Application number
NO20020829A
Other languages
English (en)
Other versions
NO20020829L (no
NO328527B1 (no
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Liu
Gar-Yang Chau
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20020829L publication Critical patent/NO20020829L/no
Publication of NO20020829D0 publication Critical patent/NO20020829D0/no
Publication of NO328527B1 publication Critical patent/NO328527B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
NO20020829A 1999-08-31 2002-02-20 Ny anvendelse av docetaxel for behandling av hepatoma NO328527B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (3)

Publication Number Publication Date
NO20020829L NO20020829L (no) 2002-02-20
NO20020829D0 true NO20020829D0 (no) 2002-02-20
NO328527B1 NO328527B1 (no) 2010-03-08

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020829A NO328527B1 (no) 1999-08-31 2002-02-20 Ny anvendelse av docetaxel for behandling av hepatoma

Country Status (34)

Country Link
US (2) US20030158249A1 (no)
EP (1) EP1214061B1 (no)
JP (1) JP4866522B2 (no)
KR (1) KR100670416B1 (no)
CN (1) CN1174748C (no)
AT (1) ATE269700T1 (no)
AU (1) AU777583B2 (no)
BG (1) BG65913B1 (no)
BR (1) BR0013625A (no)
CA (1) CA2382294C (no)
CZ (1) CZ301378B6 (no)
DE (1) DE60011794T2 (no)
DK (1) DK1214061T3 (no)
EA (1) EA004804B1 (no)
EE (1) EE05124B1 (no)
ES (1) ES2218223T3 (no)
GB (1) GB9920548D0 (no)
HK (1) HK1048944B (no)
HR (1) HRP20020171A2 (no)
HU (1) HU228861B1 (no)
IL (2) IL147489A0 (no)
ME (1) ME00624B (no)
MX (1) MXPA02002041A (no)
NO (1) NO328527B1 (no)
NZ (1) NZ517604A (no)
PL (1) PL212612B1 (no)
PT (1) PT1214061E (no)
RS (1) RS50148B (no)
SI (1) SI1214061T1 (no)
SK (1) SK286378B6 (no)
TW (1) TW589180B (no)
UA (1) UA72927C2 (no)
WO (1) WO2001015675A2 (no)
ZA (1) ZA200201408B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
ES2325506T3 (es) * 2003-12-12 2009-09-07 Quiral Quimica Do Brasil Procedimiento para la preparacion de principios activos farmaceuticos (api) anhidros e hidratados; composiciones farmaceuticas estables preparadas a partir de los mismos y usos de dichas composiciones.
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
EP1931321B1 (en) * 2005-08-31 2018-12-26 Abraxis BioScience, LLC Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
MX359413B (es) 2010-03-26 2018-09-27 Abraxis Bioscience Llc Metodos de tratamiento de carcinoma hepatocelular.
KR101752944B1 (ko) * 2010-05-03 2017-07-03 테이코쿠 팔마 유에스에이, 인코포레이티드 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
ATE178794T1 (de) * 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1999000113A1 (en) * 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
CA2628857C (en) * 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
ATE233104T1 (de) * 1997-09-18 2003-03-15 Janssen Pharmaceutica Nv Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CA2356606A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
KR20100023059A (ko) * 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법

Also Published As

Publication number Publication date
PL353198A1 (en) 2003-11-03
US20080045584A1 (en) 2008-02-21
DE60011794T2 (de) 2005-07-14
ZA200201408B (en) 2003-07-30
US20030158249A1 (en) 2003-08-21
SK2712002A3 (en) 2002-07-02
UA72927C2 (uk) 2005-05-16
HUP0203197A3 (en) 2005-01-28
AU777583B2 (en) 2004-10-21
JP2003508427A (ja) 2003-03-04
CA2382294C (en) 2008-06-03
IL147489A0 (en) 2002-08-14
NO20020829L (no) 2002-02-20
BG65913B1 (bg) 2010-05-31
HK1048944A1 (en) 2003-04-25
CN1174748C (zh) 2004-11-10
WO2001015675A2 (en) 2001-03-08
BR0013625A (pt) 2002-05-14
MEP7809A (en) 2011-12-20
CZ301378B6 (cs) 2010-02-03
TW589180B (en) 2004-06-01
KR20020060166A (ko) 2002-07-16
IL147489A (en) 2006-06-11
SK286378B6 (sk) 2008-08-05
EP1214061A2 (en) 2002-06-19
ME00624B (me) 2011-12-20
HUP0203197A2 (hu) 2003-01-28
ES2218223T3 (es) 2004-11-16
PL212612B1 (pl) 2012-10-31
EA200200313A1 (ru) 2002-08-29
SI1214061T1 (en) 2004-12-31
CA2382294A1 (en) 2001-03-08
HK1048944B (zh) 2005-04-22
HRP20020171A2 (en) 2004-02-29
NZ517604A (en) 2004-04-30
EE05124B1 (et) 2009-02-16
EP1214061B1 (en) 2004-06-23
NO328527B1 (no) 2010-03-08
DE60011794D1 (de) 2004-07-29
DK1214061T3 (da) 2004-11-01
HU228861B1 (hu) 2013-06-28
CN1372466A (zh) 2002-10-02
YU11402A (sh) 2005-07-19
BG106460A (bg) 2002-09-30
JP4866522B2 (ja) 2012-02-01
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
KR100670416B1 (ko) 2007-01-17
EE200200087A (et) 2003-04-15
WO2001015675A3 (en) 2001-09-20
MXPA02002041A (es) 2002-08-20
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
PT1214061E (pt) 2004-09-30
GB9920548D0 (en) 1999-11-03
RS50148B (sr) 2009-05-06

Similar Documents

Publication Publication Date Title
NO20020829D0 (no) Ny anvendelse av docetaxel for behandling av hepatoma
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
SE9903759D0 (sv) Pharmaceutically active compounds
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DE60128100D1 (de) Analgetisches arzneimittel
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
DE60229414D1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
SE0203817D0 (sv) New composition
ATE306940T1 (de) Zusammensetzung gegen coccidiose
ATE362480T1 (de) Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel
TW200744581A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees